MAPT and Alzheimer disease: We observed that the LRGT treatment reduces tau phosphorylation, as reported previously in AD models (Batista et al., 2018; Holubova et al., 2019; Jantrapirom et al., 2020), although to our knowledge the effects of LRGT on tau phosphorylation have not been assessed when AD-T2D coexist.